PREPRINT (not peer reviewed)

Legal and Regulatory Barriers to Medical Psilocybin Use: An International Overview

An abstract is available from the original source but is not redistributed by this tracker. Read the source record.

Open source BibTeX RIS

Bibliographic context

Journal: OSF Preprints
Date: 2025-10-02
Source: Crossref
DOI: 10.31219/osf.io/dy5cu_v1
PubMed: Unavailable

Authors

Chweikh Mohamad

Watch author

Derived topics and classifications

psilocybin Clinical Trial Healthcare Workers Clinical Trial

Citation graph

0 referenced DOIs found in stored source metadata. 0 indexed papers cite this DOI.

Open citation network

Related papers

Policy Considerations for Psychedelics in Research and Medicine - What’s Next on the Schedule?Journal of Science Policy & Governance · 2026-07-02 Psilocybin-Assisted Therapy in Psychiatry: A Narrative Clinical Review of Mechanisms, Therapeutic Applications, and Emerging Evidence (2025-2026)Journal of Clinical Medicine · 2026-08-12 Safety, feasibility, and preliminary clinical outcomes of psilocybin-assisted therapy for veterans with severe, treatment-resistant PTSD: an open-label pilot clinical trialCommunications Medicine · 2026-07-30 A Systematic Review of EEG Predictors and Correlates of Psilocybin’s Treatment in DepressionUndergraduate Research in Natural and Clinical Science and Technology (URNCST) Journal · 2026-07-27 THE PSYCHEDELIC AND KETAMINE RENAISSANCE IN THE FACE OF THE CRISIS IN MODERN PSYCHIATRYInternational Journal of Innovative Technologies in Social Science · 2026-06-14 Treatment-Resistant Depression in the 21st Century: A Scoping Review of Psychedelics and Neuromodulation in Transforming CarePremier Journal of Neuroscience · 2026-05-11 Mindfulness-Based Psilocybin-Assisted Therapy (MB-PAT) for cancer-related demoralization in Canada: The case for a hybrid group-based delivery modelPsychedelics · 2026-12-01 A suite of engineered mice for interrogating psychedelic drug actions.Nature neuroscience · 2026-08-06